Literature DB >> 20425072

Prognostic and predictive factors in the targeted therapy era: filling in the blanks.

Eric Jonasch1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20425072     DOI： 10.1007/s11912-010-0098-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  9 in total

1.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Authors:  R J Motzer; M Mazumdar; J Bacik; W Berg; A Amsterdam; J Ferrara
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

2.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Barbara A Murphy; Paul Russo; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

3.  Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.

Authors:  D Tsavachidou-Fenner; N Tannir; P Tamboli; W Liu; D Petillo; B Teh; G B Mills; E Jonasch
Journal:  Ann Oncol       Date:  2010-01-20       Impact factor: 32.976

4.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

Review 5.  Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.

Authors:  Amado J Zurita; Eric Jonasch; Hua-Kang Wu; Hai T Tran; John V Heymach
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

6.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

Authors:  Farbod Shojaei; Xiumin Wu; Ajay K Malik; Cuiling Zhong; Megan E Baldwin; Stefanie Schanz; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

7.  Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

Authors:  Tobias Klatte; P Nagesh Rao; Michela de Martino; Jeffrey LaRochelle; Brian Shuch; Nazy Zomorodian; Jonathan Said; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

8.  Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

Authors:  Trine O Jensen; Henrik Schmidt; Holger Jon Møller; Morten Høyer; Maciej Bogdan Maniecki; Pia Sjoegren; Ib Jarle Christensen; Torben Steiniche
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544

9.  Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

Authors:  Dan Huang; Yan Ding; Ming Zhou; Brian I Rini; David Petillo; Chao-Nan Qian; Richard Kahnoski; P Andrew Futreal; Kyle A Furge; Bin Tean Teh
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.